Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course

Arthritis and Rheumatism

Volumn 41, Issue 7, 1998, Pages 1173-1180

  Alarcón, Graciela S ^a   Roseman, Jeffrey ^a   Bartolucci, Alfred A ^a   Friedman, Alan W ^b   Moulds, Joann M ^b   Goel, Niti ^c   Straaton, Karin V ^a   Reveille, John D ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BEHAVIOR; CONTROLLED STUDY; DISEASE ACTIVITY; ETHNIC GROUP; FEMALE; HLA SYSTEM; HUMAN; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0031838604     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199807)41:7<1173::AID-ART5>3.0.CO;2-A     Document Type: Article

References (42)

1. Barron KS, Silverman ED, Gonzales J, Reveille JD. Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1993;36:348-54.
2. Goldstein R, Sengar DPS. Comparative studies of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with systemic lupus erythematosus. Arthritis Rheum 1993;36:1121-7.
3. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS. Anticardiolipin antibodies in systemic lupus erythematosus: clinical correlates, HLA associations, and impact on survival. J Rheumatol 1993;20:1684-93.
4. Arnett FC, Reveille JD. Genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 1992;18:865-91.
5. Olsen ML, Arnett FC, Reveille JD. Contrasting molecular patterns of MHC class II alleles associated with the anti-Sm and anti-RNP precipitin autoantibodies in systemic lupus erythematosus. Arthritis Rheum 1993;36:94-104.
6. Alarif LI, Ruppert GB, Wilson RJ, Barth WF. HLA-DR antigens in blacks with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 1983;10:297-300.
7. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Roberts WN, et al. The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus. Arthritis Rheum 1995;38:267-73.
8. Liang MH, Rogers M, Larson M, Eaton HM, Murawski BJ, Taylor JE, et al. The psychosocial impact of systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1984;27:13-9.
9. Petri M. Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991;91:345-53.
10. Studenski S, Allen NB, Caldwell DS, Rice JR, Polisson RP. Survival in systemic lupus erythematosus: a multivariate analysis of demographic factors. Arthritis Rheum 1987;30:1326-32.
11. Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus: identification of racial and socioeconomic influences. Arch Intern Med 1990;150:849-53.
12. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
13. González VM, Stewart A, Ritter PL, Lorig K. Translation and validation of arthritis outcome measures into Spanish. Arthritis Rheum 1995;38:1429-46.
14. Reveille JD, Moulds JM, Ahn C, Friedman A, Baethge B, Roseman J, et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA-class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1169-80.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
16. Straaton KV, Maisiak R, Wigley JM, Fine PR. Musculoskeletal disability, employment and rehabilitation. J Rheumatol 1995;22: 505-13.
17. Aaron LA, Bradley LA, Alarcón GS, Triana-Alexander M, Alexander RW, Martin MY, et al. Perceived physical and emotional trauma as precipitating events in fibromyalgia: associations with health care seeking and disability status but not pain severity. Arthritis Rheum 1997;40:453-60.
18. Nicassio PM, Wallston KA, Callahan LF, Herbert M, Pincus T. The measurement of helplessness in rheumatoid arthritis: the development of the Arthritis Helplessness Index. J Rheumatol 1985;12:462-7.
19. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Centers; 1994.
20. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
21. Calvo-Alén J, Bastian H, Straaton KV, Singh K, Mikhail I, Rodriguez J, et al. Use of the systemic lupus activity measure items and global: results of a training process [abstract]. Arthritis Rheum 1994;37 Suppl 9:S218.
22. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
23. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608-11.
24. Liang MH, Fortin PR, Isenberg DA, Snaith L. Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int 1991; 11:133-6.
25. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992;10:549-54.
26. Wluka AE, Liang MH, Partridge AJ, Fossel AH, Wright EA, Lew RA, et al. Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. Arthritis Rheum 1997;40:57-61.
27. Studnicka-Benke A, Steinener G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
28. Kim KL, Jones AC, Brown NS, Powell RJ. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Ann Rheum Dis 1993;52:429-35.
29. Shapira Y, Weinberger A, Wysenbeek A. Lymphadenopathy in systemic lupus erythematosus: prevalence and relation to disease manifestations. Clin Rheumatol 1996;15:335-8.
30. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AH, et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:47-56.
31. Kumar A, Malaviya AN, Singh RR, Adya CM, Kakkar R. Survival in patients with systemic lupus erythematosus in India. Rheumatol Int 1992;12:107-9.
32. Halberg P, Alsbjorn B, Balslev JT, Lorenzen I, Gerstoft J, Wiik A. Systemic lupus erythematosus: follow-up study of 148 patients. II. Predictive factors of importance for course and outcome. Clin Rheumatol 1987;6:22-6.
33. Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus 1993;2:303-12.
34. Walsh SJ, Algert C, Gregorio DI, Reisine ST, Rothfield MF. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 1995;22:1663-8.
35. Clarke AE, Bloch DA, Danoff DS, Esdaile JM. Decreasing costs and improving outcomes in systemic lupus erythematosus: using regression trees to develop health policy. J Rheumatol 1994;21: 2246-53.
36. Mody GM, Parag KB, Nathoo BC, Pudifin DJ, Duursma J, Seedat YK. High mortality with systemic lupus erythematosus in hospitalized African blacks. Br J Rheumatol 1994;33:1151-3.
37. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990;33:37-48.
38. Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus erythematosus. Ann Rheum Dis 1983;42:529-32.
39. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 1982;25:601-11.
40. Serdula MK, Rhoads GG. Frequency of systemic lupus erythematosus in different ethnic groups in Hawaii. Arthritis Rheum 1979;22:328-33.
41. Fifield J, Reisine S. Going beyond demographic characteristics in arthritis research: reflections on process in the experience of arthritis. Arthritis Care Res 1996;9:421-3.
42. Waters TM, Chang RW, Worsdall E, Ramsey-Goldman R. Ethnicity and access to care in systemic lupus erythematosus. Arthritis Care Res 1996;9:492-500.